To evaluate whether early FoxP3 or Gata3 expressions could be use to predict future progression rates, leukocytes were obtained from a larger cohort of ALS patients during the early stage of disease and were subsequently followed over a 3.5-year period. The gene discussed is GATA3; the disease is amyotrophic lateral sclerosis.